RGNX Key Statistics, Chart & Performance
The current stock price of RGNX is 13.16 USD. In the past month the price increased by 17.82%. In the past year, price increased by 37.37%.
RGNX Latest News, Press Relases and Analysis
RGNX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.92 | 399.57B | ||
| AMGN | AMGEN INC | 15.08 | 177.64B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.40B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.24 | 115.56B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.96 | 75.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 898.27 | 60.52B | ||
| INSM | INSMED INC | N/A | 43.51B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.83 | 26.60B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.54 | 21.07B | ||
| INCY | INCYTE CORP | 15.97 | 20.13B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.18B |
Related stock screener links
About RGNX
Company Profile
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Company Info
REGENXBIO INC
9804 Medical Center Drive
Rockville MARYLAND 20850 US
CEO: Kenneth T. Mills
Employees: 353
Phone: 12405528181
REGENXBIO INC / RGNX FAQ
What does REGENXBIO INC do?
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 353 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The firm is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Can you provide the latest stock price for REGENXBIO INC?
The current stock price of RGNX is 13.16 USD. The price increased by 1.39% in the last trading session.
Does RGNX stock pay dividends?
RGNX does not pay a dividend.
How is the ChartMill rating for REGENXBIO INC?
RGNX has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Where is REGENXBIO INC (RGNX) stock traded?
RGNX stock is listed on the Nasdaq exchange.
What is the Price/Earnings (PE) ratio of REGENXBIO INC (RGNX)?
REGENXBIO INC (RGNX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.47).
What is the market capitalization of RGNX stock?
REGENXBIO INC (RGNX) has a market capitalization of 666.16M USD. This makes RGNX a Small Cap stock.
RGNX Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to RGNX. When comparing the yearly performance of all stocks, RGNX is one of the better performing stocks in the market, outperforming 90.82% of all stocks.
RGNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to RGNX. The financial health of RGNX is average, but there are quite some concerns on its profitability.
RGNX Financial Highlights
Over the last trailing twelve months RGNX reported a non-GAAP Earnings per Share(EPS) of -3.47. The EPS increased by 30.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -33.88% | ||
| ROE | -110.2% | ||
| Debt/Equity | 0 |
RGNX Forecast & Estimates
19 analysts have analysed RGNX and the average price target is 32.09 USD. This implies a price increase of 143.85% is expected in the next year compared to the current price of 13.16.
For the next year, analysts expect an EPS growth of 43.33% and a revenue growth 168.34% for RGNX